A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Overview

This is an open-label, multicenter, Phase 1/2 study to determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D), and to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

SparkCures ID 1079
Trial Phase Phase 1/2
Enrollment 384 Patients
Treatments
Tags
Trial Sponsors
  • Celgene Corporation
NCT Identifier

NCT03989414

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  1. Subjects is ≥ 18 years of age and has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.
  2. Relapsed or refractory subjects must have measurable disease and have documented disease progression during or after their last anti-myeloma regimen.
  3. Newly diagnosed subjects must have documented diagnosis with previously untreated symptomatic multiple myeloma.
  4. Females of childbearing potential (FCBP) and male subjects must agree with the pregnancy prevention plan.

Exclusion Criteria:

  1. Subject has a significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
  2. Subject is unable or unwilling to undergo protocol required thromboembolism prophylaxis.

US Trial Locations

Accepting Patients

The following is a listing of trial locations that are open and accepting patients.

SparkCures Verified Accurate, up-to-date information. Learn more


Northwestern University Feinberg School of Medicine

Chicago, IL

Mayo Clinic (Rochester)

Rochester, MN

Colorado
Florida
Georgia
Verified Winship Cancer Institute of Emory University

SparkCures Verified Accurate, up-to-date information. Learn more

Illinois
Northwestern University Feinberg School of Medicine

Chicago, IL

Massachusetts
Michigan
Minnesota
Mayo Clinic (Rochester)

Rochester, MN

New Jersey
Verified John Theurer Cancer Center Hackensack Meridian Health

SparkCures Verified Accurate, up-to-date information. Learn more

North Carolina
Verified Wake Forest Baptist Comprehensive Cancer Center Wake Forest School of Medicine

SparkCures Verified Accurate, up-to-date information. Learn more

Ohio
Tennessee
Texas
Washington

Resources

There are no resources, links or videos to display for this clinical trial.

Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message